Orphan Drug Designations, Invitations to Investors Conferences, and Stock Price updates - Research Report on Teva, Cubist, Community Health Systems, Aegerion, and Air Methods

NEW YORK, December 6, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Teva Pharmaceutical Industries (NYSE: TEVA), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Community Health Systems, Inc. (NYSE: CHS), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), and Air Methods Corp. (NASDAQ: AIRM). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Teva Pharmaceutical Industries Research Report

On November 27, 2013, Teva Pharmaceutical Industries (Teva) announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug exclusivity for TREANDA all through October 2015 for indolent B-cell non-Hodgkin lymphoma (iNHL) that has advanced during or within six months of treatment with rituximab or a rituximab-containing regimen. Bill Campbell, Vice President and General Manager, Teva Oncology, commented, "Since 2008, TREANDA has played a significant role in the treatment of patients with iNHL that has progressed. We are pleased the FDA has recognized our commitment to treating patients with this rare form of cancer." Further, the Company stated that TREANDA is also indicated for the treatment of patients with chronic lymphocytic leukemia (CLL). TREANDA has been granted orphan drug exclusivity for this indication through March 2015. Teva also stated that with the previously granted six months of pediatric exclusivity for TREANDA, regulatory exclusivity for this indication will last until September 20, 2015. The Full Research Report on Teva Pharmaceutical Industries - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/e3a3_TEVA

--

Cubist Pharmaceuticals Inc. Research Report

On December 3, 2013, Cubist Pharmaceuticals Inc.'s (Cubist) stock declined 2.54%, ending the day at $65.99. Over the previous three trading sessions, shares of Cubist declined 3.21% compared to the Nasdaq Composite which also declined 0.19% during the same period. The Full Research Report on Cubist Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/92f2_CBST

--

Community Health Systems, Inc. Research Report

On December 3, 2013, Community Health Systems, Inc. (CHS) announced that its management will participate in the Oppenheimer 24th Annual Healthcare Conference, to be held on December 10-11, 2013, at the Crowne Plaza Times Square in New York City. CHS informed that the Company presentation is scheduled to begin at 8:35 a.m. ET (7:35 a.m. CT), on Tuesday, December 10, 2013. Further, a link to the broadcast will be available at the investor relations section of the Company's website, where a replay will also be available for 30 days. The Full Research Report on Community Health Systems, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/7587_CYH

--

Aegerion Pharmaceuticals, Inc. Research Report

On December 3, 2013, Aegerion Pharmaceuticals, Inc.'s (Aegerion) stock declined 2.41%, ending the day at $68.37. Over the previous three trading sessions, shares of Aegerion dropped 4.40% compared to the Nasdaq Composite which also declined 0.19% during the same period. The Full Research Report on Aegerion Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/a3f6_AEGR

--

Air Methods Corp. Research Report

On December 3, 2013, Air Methods Corp.'s (Air Methods) stock increased 0.18%, ending the day at $55.49. Over the previous three trading sessions, shares of Air Methods declined 0.38% compared to the Nasdaq Composite which also declined 0.19% during the same period. The Full Research Report on Air Methods Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/ff38_AIRM

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED